sur Viromed Medical AG (isin : DE000A3MQR65)
Viromed Medical AG Revises Revenue Forecast for 2026 Amid Growth
Viromed Medical AG, a leader in cold plasma medical technology, reported a significant revenue increase for the 2025 financial year, although it missed initial projections. Revenue soared from €1.1 million in 2024 to €5.1 million in 2025, while net income hit €0.6 million, surpassing forecasts despite revenues falling short of the targeted €8-10 million range.
Challenges in launching ViroCAP® and gaining approval for PulmoPlas® led to a revised 2026 forecast, previously set at €80 million with a double-digit EBIT margin. However, the company remains optimistic about leveraging its high market potential driven by distribution partnerships and interest in cold plasma technology applications.
Viromed anticipates substantial increases in revenue and net income for 2026, with audited results for 2025 expected by May 22, 2026.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Viromed Medical AG